Effect of Nimodipine on the Cerebral Circulation and Acute Ischemic Stroke

Ginsenoside‐Rd improves outcome of acute ischaemic stroke – a randomized, double‐blind, placebo‐controlled, multicenter trial

“…The therapeutic outcome of a neuroprotectant may depend on the specific subtype of cerebral infarction [24,25]. For example, pooled results from five randomized trials about Nimodipine on acute ischaemic stroke showed that significantly less neurologic impairment was only documented under Nimodipine treatment with moderate-to-severe stroke [26]. In this study, our subgroup analysis showed that in non-lacunar stroke, Ginsenoside-Rd markedly improved the mRs at 3 months but had no obvious effect on short- In both the intention-to-treat population and the per-protocol population, the odds for improvement integrated across all cut points of the scale were increased by ginsenoside-Rd, as compared with placebo (FAS: OR, 1.74; 95% CI, 1.08-2.78; PPS: OR, 1.80; 95% CI, 1.12-2.90).…”